Neuren Pharmaceuticals Limited
NURPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.93 | 0.00 | -53.51 | 2.53 |
| FCF Yield | -0.71% | 5.84% | 0.36% | -2.21% |
| EV / EBITDA | 8.91 | 15.81 | -1,338.86 | -50.48 |
| Quality | ||||
| ROIC | 31.19% | 64.37% | 1.04% | -45.22% |
| Gross Margin | 84.79% | 88.47% | 99.93% | 99.75% |
| Cash Conversion Ratio | -0.08 | 1.18 | 19.56 | 1.28 |
| Growth | ||||
| Revenue 3-Year CAGR | 146.07% | 317.06% | 172.78% | 86.23% |
| Free Cash Flow Growth | -106.10% | 5,064.39% | 135.87% | -23.45% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -0.09 | 55.65 | 4.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.15 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 419.03 | 13.47 | -9,389.69 | -11,015.55 |